Clinical Trial Update: BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis. [Phase 3]

View source ↗

Summary

Phase 3 BONDIR study evaluating intravenous ibandronate (Bonviva) after a recent vertebral osteoporotic fracture in patients with osteoporosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• Bonviva (ibandronic acid)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Osteoporosis | Phase 3 | Status: COMPLETED